NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

11093	Companies
243816	Keywords
171902	Articles
131319	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 11/12/2025 at 23:01, 10 months 16 days ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces closing of $6 million offering with healthcare investor. Proceeds for working capital. AGP/Alliance acted as placement agent

NanoViricides Securities Purchase Agreement Registered Direct Offering Healthcare Investor AGP/Alliance
BRIEF

published on 11/11/2025 at 14:35, 10 months 18 days ago

NanoViricides annonce une levée de fonds de 6 millions de dollars par le biais d'offres directes et de placements privés.

NanoViricides Placement Privé Bons De Souscription D'actions Offre Directe Investisseur Dans Le Secteur De La Santé
BRIEF

published on 11/11/2025 at 14:35, 10 months 18 days ago

NanoViricides Announces $6 Million Fundraising Through Direct Offering and Private Placement

Private Placement NanoViricides Direct Offering Stock Warrants Healthcare Investor
PRESS RELEASE

published on 11/11/2025 at 14:30, 10 months 18 days ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces securities purchase agreement for $6 million registered direct offering. Proceeds for working capital and corporate purposes

NanoViricides Securities Purchase Agreement Registered Direct Offering Warrants Pharmaceutical Candidates
BRIEF

published on 11/10/2025 at 14:35, 10 months 19 days ago

NanoViricides obtient l'autorisation pour un essai de phase II du NV-387 dans le traitement de la MPox

NanoViricides NV-387 Essais Cliniques Mpox Médicament Antiviral
BRIEF

published on 11/10/2025 at 14:35, 10 months 19 days ago

NanoViricides Granted Approval for Phase II Trial of NV-387 for MPox Treatment

NanoViricides NV-387 Clinical Trials Antiviral Drug Mpox
PRESS RELEASE

published on 11/10/2025 at 14:30, 10 months 19 days ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
NanoViricides, Inc. receives approval to start Phase II Clinical Trial of NV-387 for MPox treatment in the DRC. NV-387 shows promise as a broad-spectrum antiviral drug

NanoViricides NV-387 Phase II Clinical Trial Broad-spectrum Antiviral MPOX Treatment
BRIEF

published on 11/05/2025 at 14:35, 10 months 24 days ago

NanoViricides se prépare à une assemblée générale cruciale de ses actionnaires dans un contexte de préoccupations croissantes liées au MPox

NanoViricides NV-387 Essais Cliniques Médicaments Antiviraux Mpox
BRIEF

published on 11/05/2025 at 14:35, 10 months 24 days ago

NanoViricides Prepares for Critical Shareholders Meeting Amidst Rising MPox Concerns

NanoViricides NV-387 Clinical Trials Antiviral Drugs Mpox
PRESS RELEASE

published on 11/05/2025 at 14:30, 10 months 24 days ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
NanoViricides, Inc. announces Annual Shareholders Meeting to discuss progress on NV-387, a potential treatment for MPox Clade I. Clinical trials underway

NV-387 Clinical Trials NanoViricides Inc. Annual Shareholders Meeting Mpox Clade I

Accesswire

Published on 09/29/2026 at 15:05, 19 minutes ago

Banyan Gold Closes $54.3 Million Financing
Published on 09/29/2026 at 15:00, 24 minutes ago

As Crisis Events Intensify, BlackBerry and the American Red Cross Renew Commitment to Secure and Trusted Emergency Communications
Published on 09/29/2026 at 14:45, 39 minutes ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
Published on 09/29/2026 at 14:30, 54 minutes ago

Solitario Resources Presentation Change of Time at the 38th Annual Mining Forum Americas 2026 Conference
Published on 09/29/2026 at 14:30, 54 minutes ago

Hillcrest ZVS Technology Demonstrates More Than 90% Reduction in Motor Voltage Spikes

View all ACCESSWIRE

EQS Group

Published on 09/29/2026 at 15:13, 11 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 09/29/2026 at 15:12, 12 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc
Published on 09/29/2026 at 15:11, 13 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 09/29/2026 at 15:10, 14 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 09/29/2026 at 15:10, 14 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Rotork plc

Les Echos

Published on 09/29/2026 at 14:15, 1 hour 9 minutes ago

260929 BENETEAU Mise en oeuvre du programme de rachat d'actions
Published on 09/29/2026 at 12:15, 3 hours 9 minutes ago

NRJ GROUP - Affaire Fun Radio - Report du délibéré de la Cour d'appel
Published on 09/29/2026 at 08:45, 6 hours 39 minutes ago

Cegedim Santé réinvente l’accès à l’information médicale en déployant l’Assistant by Claude Bernard IA sur toutes ses solutions de médecine de ville
Published on 09/28/2026 at 17:54, 21 hours 29 minutes ago

Reporting on share buyback transactions carried out between September 21 and September 25, 2026
Published on 09/28/2026 at 17:54, 21 hours 29 minutes ago

Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 21 et le 25 septembre 2026

View all LES ECHOS COMFI WIRE